CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans-Reference-Cited by-同舟云学术

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Published:2011-03-25 Issue:6024 Volume:331 Page:1612-1616
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Beatty Gregory L.¹²³,Chiorean Elena G.⁴,Fishman Matthew P.¹,Saboury Babak⁵,Teitelbaum Ursina R.²³,Sun Weijing²³,Huhn Richard D.⁶,Song Wenru⁶,Li Dongguang⁶,Sharp Leslie L.⁶,Torigian Drew A.²⁵,O’Dwyer Peter J.²³,Vonderheide Robert H.¹²³

Affiliation:

1. Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104, USA.

2. Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

3. Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

4. Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

5. Department of Radiology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

6. Pfizer Corporation, New London, CT 06320, USA.

Abstract

CD40 immunotherapy shows efficacy in treating pancreatic cancer in mice and humans by eliciting antitumor immunity.

Funder

National Institutes of Health

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

http://www.sciencemag.org/content/331/6024/1612.full.pdf

Reference22 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

2. Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion

3. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

4. Help for cytotoxic-T-cell responses is mediated by CD40 signalling

5. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

Cited by 1396 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Barriers and opportunities in pancreatic cancer immunotherapy;npj Precision Oncology;2024-09-12

2. c-Myc alone is enough to reprogram fibroblasts into functional macrophages;Journal of Hematology & Oncology;2024-09-12

3. Single-cell analysis identifies distinct macrophage phenotypes associated with prodisease and proresolving functions in the endometriotic niche;Proceedings of the National Academy of Sciences;2024-09-10

4. The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives;International Journal of Molecular Sciences;2024-09-03

5. TIM‐4 increases the proportion of CD4⁺CD25⁺FOXP3⁺ regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL‐6 secretion;Cancer Medicine;2024-09